Search

The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.

… Wednesday, February 13, 2013 The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center. Published in the February

In order to preserve healthcare resources and provide exceptional care, our teams have been working together to develop new and innovative ways to treat our patients during the COVID-19 pandemic. MSK radiation oncologists rapidly re-evaluated our rectal cancer practice policies during this public health emergency.

… Friday, May 15, 2020 Cancer care is essential and should not be put on hold. Here at Memorial Sloan Kettering (MSK) we’ve put in place the strictest safety measures to ensure our patients continue to receive world-class cancer care in the safest environment possible. In order to preserve healthcare resources

Spinal cord compression due to spinal metastases is a medical emergency. Modern treatment approaches have fundamentally shifted the paradigm from providing short-term palliation and pain relief to delivering durable tumor control with fewer morbidities than older approaches. Therefore, cancer patients who have symptoms of spinal cord compression should be referred for surgical evaluation as soon as possible.

… Thursday, June 14, 2018 Spinal cord compression due to spinal metastases is a medical emergency. Modern treatment approaches — minimally invasive surgical techniques and spinal stereotactic radiosurgery (SSRS) — have fundamentally shifted the paradigm from providing short-term palliation and pain relief

The test, developed at MSK, looks for alterations in 468 genes that are seen in both common and rare cancers.

… Wednesday, November 15, 2017 Summary The FDA’s authorization of MSK-IMPACT sets a precedent for future authorization of tests developed by both academic and commercial labs. The US Food and Drug Administration has announced the authorization of MSK-IMPACT™ . The test was developed by Memorial Sloan Kettering

New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.

… Friday, December 20, 2024 In everyday life, when things turn out the opposite of what you expect, it’s usually cause for frustration. In science, it’s often the starting point for discovery. That’s what happened to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and their collaborators

MSK investigators are leading research focused on understanding how hereditary DNA mutations affect cancer development and therapy, and how to best treat people who carry these inherited risks in their genes.

… Monday, June 5, 2023 Researchers from Memorial Sloan Kettering Cancer Center (MSK) revealed new findings about hereditary cancers and genetics at the recent 2023 American Society of Clinical Oncology (ASCO) annual meeting. Genetic mutations that are passed down through families cause a significant percentage

Patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

… Thursday, April 12, 2007 Memorial Sloan Kettering Cancer Center’s Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib

A drug was shown to improve outcomes in women with HER2-positive early breast cancer when added to standard therapy.

… Monday, June 5, 2017 Summary Women with HER2-positive breast cancer typically receive drugs that block the HER2 protein combined with chemotherapy. A large clinical trial shows that pertuzumab reduces the risk of recurrence in certain women with breast cancer. Update: On December 20, 2017 the FDA approved

Read about how Hedvig Hricak and Lawrence Dauer have been helping the National Aeronautics and Space Administration (NASA) break down an extraterrestrial "glass ceiling."

… Thursday, July 15, 2021 Hedvig Hricak and Lawrence Dauer have been helping the National Aeronautics and Space Administration (NASA) break down an extraterrestrial “glass ceiling.” The Memorial Sloan Kettering radiation experts were contributors to a https://www.nap.edu/read/26155/chapter/1 new report

Craig B. Thompson, MD, President and CEO of Memorial Sloan Kettering Cancer Center (MSK), has been named to the first City & State Life Sciences Power 50.

… Tuesday, August 3, 2021 Craig B. Thompson, MD , President and CEO of Memorial Sloan Kettering Cancer Center (MSK), has been named to the first City & State Life Sciences Power 50 . The list recognizes the most notable individuals who are making strides in the life sciences in New York, including leaders